Publications by authors named "S Soulaidopoulos"

Background: Intracardiac echocardiography (ICE) appears to be a potential alternative for percutaneous left atrial appendage occlusion (LAAO) to transesophageal echocardiography (TEE). Thus, a meta-analysis was performed comparing ICE vs. TEE for LAAO guidance.

View Article and Find Full Text PDF

Patent foramen ovale (PFO) closure has proven to be an effective method of reducing the risk of recurrent stroke in patients with embolic stroke of unknown origin (ESUS). One of the most recognized post-procedural complications is the de novo occurrence of supraventricular arrhythmias, mainly atrial fibrillation, in the first three months following PFO closure. Earlier studies reported the incidence to be around 3.

View Article and Find Full Text PDF

Recurrent pericarditis (RP) has been traditionally regarded as a "nightmare" for both clinicians and patients. Until approximately a decade ago, available treatments were thin on the ground with non-steroidal anti-inflammatory medications, glucocorticoids, colchicine, and classical immunosuppressants being the only options. The first important step in the tale of RP was the advent of colchicine in clinical practice, which has been shown to halve the rate of first and subsequent pericarditis recurrences.

View Article and Find Full Text PDF

Atrial fibrillation (AF) is the most common arrhythmia in patients with valvular heart disease, and it can be associated with adverse patient outcomes. However, the need for anticoagulation to counterbalance AF-associated stroke risk may further lead to suboptimal outcomes via increasing bleeding events, especially in high-risk individuals. Because the vast majority of thrombi occur in the left atrial appendage, left atrial appendage occlusion (LAAO) is an established procedure for preventing ischemic stroke in patients with AF, while limiting anticoagulation-related bleeding events.

View Article and Find Full Text PDF
Article Synopsis
  • Traditional classifications of atrial fibrillation (AF) are evolving, now seen as a continuous variable instead of just paroxysmal, persistent, or permanent forms, highlighting the importance of AF burden, which measures the duration of AF episodes.
  • This review discusses how AF burden is measured, its effect on patient outcomes, and the need for personalized strategies that consider both AF burden and clinical scores like CHADS-VASc, although current studies call these approaches into question.
  • Continuous monitoring technologies have potential benefits for managing AF, but challenges remain in setting clinically relevant thresholds; future research should aim to refine these metrics and evaluate interventions to reduce AF burden for better patient care.
View Article and Find Full Text PDF